Reduced neutralization of SARS-CoV-2 variants by convalescent plasma and hyperimmune intravenous immunoglobulins for treatment of COVID-19
J. Tang, Y. Lee, S. Ravichandran, G. Grubbs, C. Huang, C. Stauft, T. Wang, B. Golding, H. Golding, S. Khurana
This study evaluates the neutralization capacity of hyperimmune immunoglobulins and convalescent plasma against SARS-CoV-2 and its variants, finding reduced effectiveness against certain variants with hCoV-2IG showing better cross-neutralization than convalescent plasma.
bioRxiv · Mar 19, 2021Immunology